Synopsys rises on FY2027 guidance beat, but thesis still waits for execution

What happened

Synopsys shares traded higher Thursday after the company issued fiscal-year 2027 financial guidance above consensus estimates, as reported by Benzinga. This announcement follows a period of stock volatility and likely accompanied the September 30 Investor Day, a key catalyst highlighted in the prior analysis. The previous WAIT rating was driven by a rich valuation (95x earnings, 36x EV/EBITDA) and unresolved concerns around Design IP weakness and delayed customer drawdowns. While the guidance beat signals management confidence in sustained AI-driven demand, it does not yet address the missing proof on Ansys cross-sell economics or China-related pressure. Investors should treat this as a modest positive but not a thesis-changing event until segment results confirm stabilization.

Implication

The FY2027 guidance above estimates is a mild positive, suggesting management expects AI tailwinds to continue. However, the stock still trades at roughly 95x trailing earnings and 36x EV/EBITDA, leaving little room for error. Key risks remain Design IP contraction and delayed customer drawdowns, especially in China. Without hard cross-sell metrics from Ansys, the integration thesis remains unproven. Therefore, maintain a WAIT stance and look for entry below $380 or after two quarters of sustained improvement.

Thesis delta

Prior thesis was WAIT due to premium valuation and lack of proof on integration and IP stabilization. The news of above-consensus FY2027 guidance modestly improves near-term sentiment but does not alter the core wait-and-see stance. If subsequent filings confirm Design IP stabilization and disclose synergy economics, the rating would improve.